OpGen (NASDAQ:OPGN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Friday. The firm presently has a $2.50 target price on the medical research company’s stock. Zacks Investment Research‘s target price indicates a potential upside of 8.23% from the company’s previous close.
According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “
A number of other brokerages have also issued reports on OPGN. ValuEngine upgraded OpGen from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. HC Wainwright raised their target price on OpGen to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, February 7th.
A hedge fund recently raised its stake in OpGen stock. Vanguard Group Inc. boosted its stake in shares of OpGen Inc (NASDAQ:OPGN) by 1.6% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 342,860 shares of the medical research company’s stock after purchasing an additional 5,500 shares during the period. Vanguard Group Inc. owned approximately 1.25% of OpGen worth $219,000 at the end of the most recent quarter.
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.